Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME) ; volume:13 ; number:8 ; day:4 ; month:6 ; year:2024 ; pages:2163-2184 ; date:8.2024
Ophthalmology and therapy ; 13, Heft 8 (4.6.2024), 2163-2184, 8.2024

Creator
Giancipoli, Ermete
Guglielmi, Antonella
Bux, Anna Valeria
Clima, Giulia Maria Emilia
Pignatelli, Francesco
Boscia, Francesco
Viggiano, Pasquale
Boscia, Giacomo
Fortunato, Francesca
Besozzi, Gianluca
Niro, Alfredo
Dore, Stefano
Iaculli, Cristiana
Contributor
SpringerLink (Online service)

DOI
10.1007/s40123-024-00980-5
URN
urn:nbn:de:101:1-2410020927047.766921652195
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Giancipoli, Ermete
  • Guglielmi, Antonella
  • Bux, Anna Valeria
  • Clima, Giulia Maria Emilia
  • Pignatelli, Francesco
  • Boscia, Francesco
  • Viggiano, Pasquale
  • Boscia, Giacomo
  • Fortunato, Francesca
  • Besozzi, Gianluca
  • Niro, Alfredo
  • Dore, Stefano
  • Iaculli, Cristiana
  • SpringerLink (Online service)

Other Objects (12)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration

The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration

Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration

Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration

Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration

Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up

The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD

The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD

Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study

Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study

Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review

Factors Affecting Disease Stability After Intravitreal Brolucizumab Injection for Refractory Neovascular Age-Related Macular Degeneration

Factors Affecting Disease Stability After Intravitreal Brolucizumab Injection for Refractory Neovascular Age-Related Macular Degeneration

Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis

Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis

Related objects